| Purpose:To observe the clinical efficacy and adverse reactions of Sacubitril Valsartan in the treatment of chronic heart failure(CHF),and to analyze the effect of its on blood pressure.Method:A total of 102 patients with essential hypertension and chronic heart failure who were diagnosed and treated in the third affiliated hospital of Nanchang University from September 2018 to October 2020 were divided into two groups: the experimental group(51 cases)and the control group(51 cases).On the basis of conventional anti heart failure,the experimental group was given oral Sacubitril Valsartan of 50 mg / time,twice a day,which was increased to 100 mg / time,twice a day according to tolerance;the control group was given oral Valsartan of 80 mg / time,twice a day,on the basis of conventional anti heart failure.The treatment lasted for 3months in both groups.The clinical effect and the improvement of blood pressure,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diamension(LVEDD),n-terminal pro-brain natriuretic peptide(NT-pro BNP)and cardiac function were observed before and after treatment.,at the same time,the effect of two groups of treatment on blood pressure level was analyzed.Results:After 3 months of treatment,the effective rate of the experimental group was86.3%(44/51),and that of the control group was 70.6%(36/51).The difference between the two groups was statistically significant(c2= 7.283,p = 0.026).After treatment,LVEF,LVEDD and NT-pro BNP were improved in both groups,and the improvement was more obvious in the experimental group than in the control group.LVEF(8.59±6.17vs6.04±2.91p<0.05),LVEDD(4.00(2.00-7.00)vs 2.00(0.00-4.00),NT-pro BNP(4919.00(2124.00-6658.00)vs 2720.00(1200.00-4270.00)p < 0.05)was statistically significant.The systolic and diastolic blood pressure in the two groups decreased significantly after treatment,and the improvement of blood pressure in the test group was more significant than that in the control group.Before and after treatment,the improvement of blood pressure was compared between the two groups.There were significant differences in systolic blood pressure(36.00±9.05 vs 23.61±4.96 p < 0.05)and diastolic blood pressure(17.00(13.00-20.50)vs 11.00(9.00-15.00)p < 0.05).There were 4 cases of adverse reactions in the experimental group(7.8%),and 3 cases in the control group(5.9%).There was no significant difference in the incidence of adverse reactions between the two groups(P < 0.05).Conclusion:1.In the treatment of chronic heart failure by Sacubitril Valsartan,the levels of LVEF,LVEDd,NT-pro BNP and cardiac function can be significantly improved with good clinical efficacy;2.On the level of blood pressure,the antihypertensive effect of Sacubitril Valsartan is significant,which has good clinical significance;3.Compared with Valsartan,Sacubitril Valsartan has no significant difference in the incidence of adverse reactions,high safety,and more significant efficacy,and is worthy of further promotion in clinical application. |
